ScholarLens Back to search
2014•Practical Journal of Clinical MedicineRequires access

Correlation between expression of ERCC1 and recent curative effect of oxaliplatin chemotherapy in advanced gastric cancer

Yuan Zhang-bi

Open publisher page 0 citations

Abstract

Objective To investigate the relationship between expression of excision repair cross-complementation group 1( ERCC1) and curative effect of oxaliplatin chemotherapy in advanced gastric carcinoma. Methods Fifty-six patients with evaluable metastasis were selected for this study. They were treated with oxaliplatin chemotherapy,and meanwhile the expression level of ERCC1was detected. The relationship between ERCC1 expression and disease control response( DCR) were analyzed. Results In 56 patients,26 were progressive disease( PD),12 were stable disease( SD),and 18 were partial remission( PR),but nobody was complete remission( CR). The disease control rate was 53. 57%. There were 20 cases having ERCC1 expression( 35. 7%). The expression of ERCC1 was associated with the chemotherapy( χ2= 6. 95,P = 0. 009),and showed a strong negative correlation( r =-0. 821). Conclusion ERCC1 gene expression in advanced gastric cancer tissue can be used as a predictive guidance for efficacy of oxaliplatin chemotherapy.

About this research paper

What this paper is about

Objective To investigate the relationship between expression of excision repair cross-complementation group 1( ERCC1) and curative effect of oxaliplatin chemotherapy in advanced gastric carcinoma. Methods Fifty-six patients with evaluable metastasis were selected for this study. They were treated with oxaliplatin chemotherapy,and meanwhile the expression level of ERCC1was detected. The relationship between ERCC1 expression and disease control response( DCR) were analyzed. Results In 56 patients,26 were progressive disease( PD),12 were stable disease( SD),and 18 were partial remission( PR),but nobody was complete remission( CR). The disease control rate was 53. 57%. There were 20 cases having ERCC1 expression( 35. 7%). The expression of ERCC1 was associated with the chemotherapy( χ2= 6. 95,P = 0. 009),and showed a strong negative correlation( r =-0. 821). Conclusion ERCC1 gene expression in advanced gastric cancer tissue can be used as a predictive guidance for efficacy of oxaliplatin chemotherapy.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To investigate the relationship between expression of excision repair cross-complementation group 1( ERCC1) and curative effect of oxaliplatin chemotherapy in advanced gastric carcinoma. Methods Fifty-six patients with evaluable metastasis were selected for this study. They were treated with oxaliplatin chemotherapy,and meanwhile the expression level of ERCC1was detected. The relationship between ERCC1 expression and disease control response( DCR) were analyzed. Results In 56 patients,26 were progressive disease( PD),12 were stable disease( SD),and 18 were partial remission( PR),but nobody was complete remission( CR). The disease control rate was 53. 57%. There were 20 cases having ERCC1 expression( 35. 7%). The expression of ERCC1 was associated with the chemotherapy( χ2= 6. 95,P = 0. 009),and showed a strong negative correlation( r =-0. 821). Conclusion ERCC1 gene expression in advanced gastric cancer tissue can be used as a predictive guidance for efficacy of oxaliplatin chemotherapy.

Key concepts: Medicine, Oxaliplatin, ERCC1, Chemotherapy, Internal medicine, Oncology, Cancer, Colorectal cancer

Back to paper searchBrowse research topicsOriginal source
Correlation between expression of ERCC1 and recent curative effect of oxaliplatin chemotherapy in advanced gastric cancer — Research Paper | ScholarLens